Cerebral Cavernous Malformations (CCM) are leaky vascular lesions that cause hemorrhagic strokes, seizures, and neurological deficits. Familial CCM type 1 (fCCM1) is an autosomal dominant disease caused by mutations in the KRIT1 gene, and is typically characterized by multiple lesions on MRI that increase in number and size over time. Patients present with marked variability of disease burden, even among carriers of the same gene mutation, family or age. Currently only neurosurgical options are available to patients, although recent data from CCM animal models show promising benefits of drugs that target RhoA (statins and fasudil) for stabilizing endothelial junctions and reducing vascular leakage. In this project, we will leverage our considerable efforts over the past 5 years to recruit, phenotype, and identify modifiers of CCM disease severity in fCCM1 patients with the same founder mutation (Q455X), known as the Common Hispanic Mutation (CHM). Our long-term goal is to identify biomarkers for disease severity, which could aid in identifying patients at high risk for hemorrhage who would benefit most from pharmacologic therapy, and sets the stage for future clinical treatment trials. In the next funding period, we will continue longitudinal follow-up of 300 CCM1-CHM cases to ascertain outcomes and better understand the natural history of the disease, build on our existing genome wide association data to investigate the role of inflammation in CCM, and expand our focus on biomarker development for clinical trials, including gene expression and neuroimaging biomarkers. We will recruit a replication cohort of 300 fCCM1 cases caused by CHM and other CCM1 gene mutations to assess generalizability of findings in the CCM1-CHM cohort, and collect new data for follow-up studies (including plasma and serum samples, and surgically resected tissue specimens). We propose the following aims:
Aim 1 : To longitudinally characterize the phenotypic expression and natural history of CCM1-CHM patients.
Aim 2 : To investigate the role of inflammation in CCM1 disease progression.
Aim 3 : To develop biomarkers predictive of disease severity and progression for medical treatment of CCM.

Public Health Relevance

Genetic forms of cerebral cavernous malformations are characterized by multiple cavernous malformations of the central nervous system with marked variability of disease severity among affected patients based on hemorrhage, new lesion formation and growth overtime. This large, well-characterized cohort of CCM1 patients provides the opportunity to identify modifiers of disease severity and biomarker development.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZTR1)
Program Officer
Moy, Claudia S
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
San Francisco
United States
Zip Code
Walcott, Brian P; Choudhri, Omar; Lawton, Michael T (2016) Brainstem cavernous malformations: Natural history versus surgical management. J Clin Neurosci 32:164-5
Choquet, Hélène; Trapani, Eliana; Goitre, Luca et al. (2016) Cytochrome P450 and matrix metalloproteinase genetic modifiers of disease severity in Cerebral Cavernous Malformation type 1. Free Radic Biol Med 92:100-9
Kavanaugh, Brian; Sreenivasan, Aditya; Bachur, Catherine et al. (2016) [Formula: see text]Intellectual and adaptive functioning in Sturge-Weber Syndrome. Child Neuropsychol 22:635-48
Merkel, Peter A; Manion, Michele; Gopal-Srivastava, Rashmi et al. (2016) The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network. Orphanet J Rare Dis 11:66
Walcott, Brian P; Winkler, Ethan A; Rouleau, Guy A et al. (2016) Molecular, Cellular, and Genetic Determinants of Sporadic Brain Arteriovenous Malformations. Neurosurgery 63 Suppl 1:37-42
Kaplan, Emma H; Kossoff, Eric H; Bachur, Catherine D et al. (2016) Anticonvulsant Efficacy in Sturge-Weber Syndrome. Pediatr Neurol 58:31-6
Krings, T; Kim, H; Power, S et al. (2015) Neurovascular manifestations in hereditary hemorrhagic telangiectasia: imaging features and genotype-phenotype correlations. AJNR Am J Neuroradiol 36:863-70
Golden, Michael; Saeidi, Saba; Liem, Benny et al. (2015) Sensitivity of patients with familial cerebral cavernous malformations to therapeutic radiation. J Med Imaging Radiat Oncol 59:134-6
Choquet, H; Pawlikowska, L; Lawton, M T et al. (2015) Genetics of cerebral cavernous malformations: current status and future prospects. J Neurosurg Sci 59:211-20
Comi, Anne M (2015) Sturge-Weber syndrome. Handb Clin Neurol 132:157-68

Showing the most recent 10 out of 34 publications